$CRBU News

In the hunt for reverse merger targets, Caribou could be prized game

HC Wainwright & Co. Downgrades Caribou Biosciences to Neutral

Caribou to halt CAR-T work, lay off staff amid ‘challenging’ funding climate

CAR-T specialist Caribou culls pipeline and seeks exit deal

Brookline Capital Downgrades Caribou Biosciences to Hold

CRBU Stock Crashes 35% Premarket — RBC Slashes Target By 90% After Caribou Scraps CAR-T Programs

RBC Capital Downgrades Caribou Biosciences to Sector Perform, Lowers Price Target to $1

Leerink Partners Downgrades Caribou Biosciences to Market Perform, Lowers Price Target to $1

Caribou Biosciences (CRBU) Shares Fall 35% After Hours: Here's Why

Caribou Biosciences stock plunges 40% on halt of CAR-T programs

Caribou Biosciences to Evaluate Strategic Alternatives

Caribou Biosciences Mulls Strategic Options To Maximize Shareholder Value; Intends To Discontinue Further Development Activities For Two Allogeneic CAR-T Cell Therapy Programs

Caribou Biosciences (CRBU) Loses 19.6% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner

B of A Securities Maintains Buy on Caribou Biosciences, Lowers Price Target to $5

Caribou Biosciences, Inc. (CRBU) Reports Q2 Loss, Lags Revenue Estimates

Caribou Biosciences Reports Second Quarter 2026 Financial Results and Provides Business Update

Caribou Biosciences Q2 EPS $(0.24) Beats $(0.32) Estimate, Sales $1.499M Miss $2.279M Estimate

Are Medical Stocks Lagging Caribou Biosciences (CRBU) This Year?

Caribou Biosciences to Participate in the H.C. Wainwright 4th Annual Cell Therapy Virtual Conference

Caribou Biosciences, Inc. (CRBU) Presents at European Hematology Association (EHA) 2026 Congress - Slideshow